- Home
- CYPH vs TCRX Comparison
CYPH vs TCRX Comparison
Compare CYPH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYPH | TCRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 57.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYPH | TCRX |
|---|---|---|
| Price | $0.64 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.1M | 455.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,816,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.88 |
| 52 Week High | $3.70 | $2.57 |
Technical Indicators
Market Signals| Indicator | CYPH | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 52.25 |
| Support Level | $0.57 | $0.90 |
| Resistance Level | $0.80 | $1.23 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 23.18 | 65.15 |
Price Performance
Historical ComparisonAbout CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a company developing novel therapies for patients with cancer and implementing a digital asset treasury plan focused on Zcash.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.